Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality

Mohammadreza Bozorgmanesh1, Farzad Hadaegh1*, Farhad Sheikholeslami1, Arash Ghanbarian1 and Fereidoun Azizi2

Abstract

Background: We contrasted impacts on all-cause and cardiovascular disease (CVD) mortality of diabetes vs. CVD.

Methods: Among participants the Tehran lipid and glucose study aged ≥ 30 years (n = 9752), we selected those who participated in the follow-up study until 20 March 2009 (n = 8795). Complete data on covariate were available for 8,469 participants, contributing to a 67,935 person-year follow up. In the analysis of outcomes (all-cause and CVD mortality), diabetes and CVD were assessed using Cox proportional hazard regression model adjusting for established CVD risk factors. We used population attributable hazard fraction (PAHF) and rate advancement period (RAP) that expresses how much sooner a given mortality rate is reached among exposed than among unexposed individuals.

Results: Ten percent of the participants self-reported to have previous CVD, and diabetes was ascertained in 17% of participants at baseline examination. During a median follow-up of 9 years 386 participants died of which 184 were due to CVD. All-cause and CVD mortality rate (95% CIs) were 5.5 (5.0-6.1) and 2.6 (2.3-3.0) per 1000 person-year, respectively. The PAHF of all-cause mortality for diabetes 9.2 (7.3-11.1) was greater than the one for CVD 3.5 (1.1-5.5). RAP estimates for all-cause mortality associated with diabetes ranged from 7.4 to 8.6 years whereas the RAP estimates for all-cause mortality associated with CVD ranged from 3.1 to 4.3 years. The PAHF of CVD mortality for diabetes 9.4 (6.8-12.0) was greater than the one for CVD 4.5 (1.8-7.0). RAP estimates for CVD mortality associated with diabetes ranged from 8.2 to 9.8 years whereas the RAP estimates for CVD mortality associated with CVD ranged from 4.7 to 6.7 years.

Conclusions: We demonstrated that diabetes, which was shown to be keeping pace with prevalent CVD in terms of conferring excess risk of incident CVD, is currently causing more deaths in the population than does CVD.

Keywords: Cardiovascular disease, Diabetes, Mortality, Population-attributable mortality

Background

Mortality is an important measure of population health and is often used to assign priorities in health interventions [1,2]. Cardiovascular disease (CVD) has long been known as the leading cause of mortality and morbidity in developed countries [3]. The recognition and management of cardiovascular risk factors led to a decline in CVD related mortality rates in the 1960s. However, the increases in the prevalence of type 2 diabetes mellitus (hereafter diabetes) and obesity are potential warning signs that the hard-fought gains in mortality improvements might be arrested or even reversed [4,5]. The World Health Report 1999 estimates that in 1998, 78% of the burden of non-communicable diseases and 85% of the CVD burden arose from the low and middle income countries [6]. The high burdens of CVD in the developing countries are attributable to the increasing incidence of atherosclerotic diseases, perhaps due to urbanization [7-9]. Diabetes is not only a current common disease but its prevalence is expected to increase, especially in...
developing countries [10,11]. The target organ damage has been observed to increase the risk of cardiovascular complications independently of the existing estimated risk [12].

Diabetes has been shown by some studies to be a CVD equivalent in contribution to the CVD mortality in some studies [13-17]. These studies have solely relied on relative risk, while neglecting the prevalence of the diabetes and CVD. Furthermore, diabetes and CVD have never been weighted against each other with respect to the all-cause mortality. Routinely reported statistics based on death certification seriously underestimate mortality from diabetes. In fact, mortality from diabetes is underestimated four- to fivefold by methods of analysis of death certification data which use only underlying cause of death [13]. Individuals with diabetes most often die of cardiovascular and renal disease and not from a cause uniquely related to diabetes, such as ketoacidosis or hypoglycemia [14]. Therefore, mortality attributable to diabetes could be expected to be much higher, since diabetes is a serious and chronic condition. Although some developed countries have documented an improved survival of persons with diabetes, the increased prevalence is most likely due to increased incidence rather than improved survival [15].

Population risks of CVD and all-cause mortality due to diabetes have been previously documented in different population [16,17]. It has also been shown that population-attributable risk fraction should be periodically recalculated so that we can adequately capture trends in the population [18]. As the issue is of considerable clinical importance, particularly for public health strategies aimed at reducing mortality, we contrasted the population-wide impacts on the all-cause and CVD mortality of diabetes vs. CVD. We used population attributable hazard fraction (PAHF) as an epidemiologic tool which takes into account the prevalence of risk factors as well as the strength of their associations with mortality and guides policymakers in planning public health interventions priorities [19].

Methods
Study population
Detailed descriptions of the Tehran lipid and glucose study (TLGS) have been reported elsewhere [20,21]; in brief, the TLGS is a large scale, long term, community-based prospective study performed on a representative sample of residents of district No. 13 of Tehran, capital of Iran. Age and sex distributions of the population in the district were representative of the overall population of Tehran at the time of the baseline examination. The TLGS, has two major components: a cross-sectional prevalence study of non-communicable disease and associated risk factors, implemented between March 1999 and December 2001, and a prospective follow-up study. Data collection is ongoing, designed to continue for at least 20 years, at 3-year intervals. A total of 27340 residents aged ≥3 years were invited by telephone call, of which 15,010 residents participated in first examination cycle and another 3,551 residents were first examined at the second examination cycle. Participants were categorized into the cohort (n = 10 394) and intervention groups (n = 8 167), the latter to be educated for implementation of life style modifications. For the current study, among participants aged ≥30 years (n = 9 752), we selected those who participated in the follow-up study until 20 March 2009 (n = 8,795). Complete data on covariate were available for 8,469 participants, contributing to a 67,935 person-year follow up. At the time of this study, the median follow up time was 9 years.

Clinical and laboratory measurements
A trained interviewer collected information using a pre-tested questionnaire. The information obtained included demographic data, drug history, past medical history of CVD, hypertension, and diabetes and smoking status [22]. After a 15-minute rest in the sitting position, two measurements of blood pressure were taken, on the right arm, using a standardized mercury sphygmomanometer (calibrated by the Iranian Institute of Standards and Industrial Researches); the mean of the two measurements was considered as the participant’s blood pressure.

A blood sample was drawn between 7:00 and 9:00 AM from all study participants, after 12 to 14 hours overnight fasting. All the blood analyses were undertaken at the TLGS research laboratory on the day of blood collection. Plasma glucose was measured using an enzymatic colorimetric method with glucose oxidase. Fasting plasma glucose (FPG) measurement was performed for all participants, and the standard 2-hour post-challenge plasma glucose (2 h-PCPG) test for those not on glucose-lowering drugs. Total cholesterol (TC) was assayed, using the enzymatic colorimetric method with cholesterol esterase and cholesterol oxidase. High-density lipoprotein cholesterol (HDL-C) was measured after precipitation of the apolipoprotein B containing lipoproteins with phosphotungstic acid. Analyses were performed using Pars Azmon kits (Pars Azmon Inc., Tehran, Iran) and a Selectra 2 auto-analyzer (Vital Scientific, Spankeren, Netherlands). All samples were analyzed when internal quality control met the acceptable criteria. The intra and inter-assay coefficients of variation were both <2.2% for plasma glucose, and 0.5 and 2% for TC, respectively [20].

Outcome measurements
Details of cardiovascular outcomes have been published elsewhere [23]. In this ongoing study every TLGS’
participant is followed up for any medical event during the previous year, by telephone. They are questioned by a trained nurse regarding any medical conditions or whether a related event have occurred, a trained physician collects complementary data during a home visit and/or a visit to the respective hospital to collect data from the participants medical files. In the case of mortality, data are collected from the hospital or the death certificate by an authorized local physician. Collected data are evaluated by an outcome committee consisting of a principal investigator, an internist, an endocrinologist, a cardiologist, an epidemiologist, and the physician who collects the outcome data. Other experts are invited for evaluation of non-communicable disorders, as needed. A specific outcome for each event is assigned according to International Statistical Classification of Diseases and Related Health Problems criteria, 10th Revision, and American Heart Association classification for cardiovascular events [20,24,25]. Coronary heart disease (CHD) includes cases of definite myocardial infarction (MI) diagnosed by electrocardiogram (ECG) and biomarkers, probable MI (positive ECG findings plus cardiac symptoms or signs and biomarkers showing negative or equivocal results), unstable angina pectoris (new cardiac symptoms or changing symptom patterns and positive ECG findings with normal biomarkers), angiographic proven CHD and CHD death.

CVD is specified as a composite measure of any CHD events, stroke, or cerebrovascular death.

**Definition of terms**

Current smoker was defined as a person who smokes cigarettes daily or occasionally. A previous history of CVD reflected any prior diagnosis of CVD by a physician. In accordance with the definition provided by American Diabetes Association, participants were classified as having diabetes at the baseline if they met at least one of these criteria: FPG $\geq$ 7 mmol.l$^{-1}$, or 2 h-PCPG $\geq$ 11.1 mmol.l$^{-1}$ or taking anti-diabetic medication [16].

**Statistics analysis**

Findings on covariate variables are expressed as means (SD) or percentages for continuously distributed and categorical variables, respectively.

In the analysis of outcomes (all-cause and CVD mortality), diabetes and CVD were assessed using Cox proportional hazard regression model. Survival time was the time from start of the follow-up period to the date of the first incident, CVD event or death (failure). The censoring time of an individual was the time from entry into the study to loss to follow-up or the end of the study (20th March 2009), whichever happened first. Censored observation meant the individuals either refused to participate further in the study (lost to follow-up), died (from non-CVD causes), when death was not the study outcome (competing risk) or continued until 20th March 2009 when the study was ended (administrative censoring). Potential confounding effects of age, smoking, systolic blood pressure, use of anti-hypertensive drugs, lifestyle modification intervention, total and HDL cholesterol were accounted for in the multivariate regression models. We also examined if direction or magnitude of the association of diabetes and CVD with different endpoints were modified by intervention, or each other. As such, the interaction term for intervention $\times$ diabetes, intervention $\times$ CVD, and diabetes $\times$ CVD were introduced into regression models. The significance of interactions (lack of independence) was tested by likelihood ratio test.

Wald tests of the linear hypotheses concerning the Cox regression models coefficients (paired homogeneity test) were performed to test the null hypotheses that the hazard ratios (effect size) for diabetes were equal to those for CVD.

Recently, Chen et al. and Samuelsen et al. have proposed a definition for population-attributable fraction (PAF) for cohort studies with time-to-event, i.e. Population Attributable Hazard Fraction (PAHF). The PAHF is defined based on the effect of the hypothetical risk factor modification to the low-risk level; it is estimated at the instantaneous time point $t$:

$$\text{PAHF} = \frac{p(t)(HR(t) - 1)}{1 + p(t)(HR(t) - 1)},$$

where $p$ is proportion exposed at time $t$ and $HR(t) = \frac{h(t)}{h_1(t)}$ denotes instantaneous hazard ratio at time $t$ [26,27]. This measure describes the approximate proportion of events that could be avoided by the risk factor modification in a short time interval $[t, t+\Delta t]$, where $\Delta t = 0$. We used proportion exposed at baseline, $p = p(0)$ as suggested [27,28]. As such the formula corresponds to the traditional PAF [29] formula as was presented in the literatures by Levin [19].

Rate advancement period (RAP) has been encouraged to be used as an effective risk communication tool. It expresses how much sooner a given mortality rate is reached among exposed than among unexposed individuals [30]. RAPs for diabetes and CVD were calculated in years as suggested by literature [31].

**Participants and adjustment for potential selection bias**

Baseline age, use of anti-hypertensive drugs, systolic blood pressure, smoking, diabetes, and history of CVD, were included in the logistic model with participation as outcome. The probability of participation was estimated using logistic model and used as a propensity score. We added this propensity score to the survival models as a covariate and examined if the probability of participation
was associated with incident CVD or mortality. The probability of participation was not associated with any of the outcomes under the investigation (P values > 0.8) and the parameter estimates remained essentially unchanged. Therefore, the selection bias is unlikely to have affected our estimations.

We set the statistical significance level at a two-tailed type I error of 0.05. All statistical analyses were performed using STATA version 12 (STATA, College Station, Texas USA).

Medical ethics
We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research. Informed written consent was obtained from all participants and the Ethical Committee of the Research Institute for Endocrine Sciences approved this study.

Results
Baseline characteristics of the participants are presented in Table 1. Mean age of the participants was 33.3 years (19.0). Ten percent of the participants self-reported to have previous CVD, and diabetes was ascertained in 17% of participants at baseline examination. During a median follow-up of 9 years 386 participants died of which 184 were due to CVD. All-cause and CVD mortality rate (95% CIs) were 5.5 (5.0-6.1) and 2.6 (2.3-3.0) per 1000 person-year, respectively.

Among women, effects of diabetes and CVD on all-cause and CVD mortality were independent of each other. However, among men diabetes and CVD mutually modified effects of each other. Therefore, we excluded participants with both diabetes and CVD; as such we compared participants with diabetes/without CVD with those with CVD/without diabetes. Nonetheless, the point estimates for PAHF's and RAP remained essentially unchanged. To avoid complexity, thus, we reported results obtained from original sample assuming that diabetes and CVD independently contributed to the all-cause and CVD mortality (data not shown). The intervention did not contributed to the incidence of the outcomes under the investigation, neither did it modify the effects of CVD or diabetes on the outcomes (P values > 0.2).

Table 2 presents the comparative quantification of CVD and all-cause mortality attributable to diabetes and history of previous CVD. The HRs for all-cause mortality of diabetes was greater than those of CVD. The difference, however, did not achieve statistical significance among men. The PAHF of all-cause mortality for diabetes 9.2 (7.3-11.1) was greater than the one for CVD 3.5 (1.1-5.5). RAP estimates for all-cause mortality associated with diabetes ranged from 7.4 to 8.6 years whereas the RAP estimates for all-cause mortality associated with CVD ranged from 3.1 to 4.3 years.

Tables 3 and 4 presents the comparative quantification of CVD and all-cause and CVD mortality attributable to diabetes and history of previous CVD. The HRs for CVD mortality of diabetes was greater than those of CVD. The difference, however, did not achieve statistical significance. The PAHF of CVD mortality for diabetes 9.4 (6.8-12.0) was greater than the one for CVD 4.5 (1.8-7.0). RAP estimates for CVD mortality associated with diabetes ranged from 8.2 to 9.8 years whereas the RAP estimates for CVD mortality associated with CVD ranged from 4.7 to 6.7 years.

Discussion
Using data from a well-characterized prospective cohort study of men and women, we comparatively quantified the population-wide burden of all-cause and CVD mortality attributable to diabetes and CVD. We observed that population mortality conferred by diabetes is not lower than those conferred by previous CVD events. In fact, among women population mortality from any cause conferred by diabetes was significantly higher than those

| Table 1 Characteristics of the participants |
|-----------------|-----------------|-----------------|
| **Women**       | **Men**         | **Total**       |
| Observations (n) | 4,762           | 4,033           | 8,795           |
| Age (year)       | 33.24 (18.23)   | 33.34 (19.97)   | 33.29 (19.01)   |
| Systolic blood pressure (mmHg) | 114.62 (19.41) | 115.88 (18.32) | 115.17 (18.95) |
| Total cholesterol (mmol/l) | 5.2 (1.26)      | 4.95 (1.13)     | 5.09 (1.21)     |
| High-density lipoprotein Cholesterol (mmol/l) | 1.16 (0.28)     | 1.04 (0.26)     | 1.11 (0.28)     |
| Antihypertensive drug (users vs. non-users) | 978 (0.21)      | 466 (0.12)      | 1,444 (0.16)    |
| Current Smoking (smokers vs. non-smokers) | 185 (0.04)      | 1,151 (0.30)    | 1,336 (0.15)    |
| History of cardiovascular disease (yes vs. no) | 373 (0.09)      | 542 (0.11)      | 915 (0.10)      |
| Diabetes (yes vs. no) | 631 (0.16)      | 818 (0.18)      | 1,449 (0.17)    |
| Cardiovascular mortality (per 1000 person-year) | 1.5 (1.1-1.9)   | 4.0 (3.4-4.8)   | 2.6 (2.3-3.0)   |
| All-cause mortality (per 1000 person-year) | 3.6 (3.1-403)   | 7.8 (6.9-8.8)   | 5.5 (5.0-6.1)   |
conferred by previous CVD. We also applied the concept of RAP that provides an excellent translation into lay language. Accordingly, we observed that diabetic patients died 7–10 years sooner than did those without diabetes and that patients with previous CVD died 3–7 years sooner than did those without CVD.

The PAHF, which incorporates both risk factor prevalence and its predictive value (i.e., relative or excess risk), provide a measure of effectiveness that can be broadly helpful in deciding which risk factor should be targeted by health interventions [7]. Our finding shows that mortality could be reduced twice as much by elimination from the population of diabetes as by elimination from the population of CVD.

Beverly Levine [33] argued that the most illuminating questions about the attributable fraction are: What interventions are available to cause the assumed reduction in risk among the exposed and the consequent estimated reduction in disease burden? What proportion of disease risk could be eliminated if the absolute risk in the exposed were to suddenly and sustainably go to the level of absolute risk in the unexposed, while nothing else, including absolute risk in the unexposed, were to change?

While there is no doubt that diabetes harbors a causal effect on CVD [34–38] and all-cause mortality [36,39,40], whether these effects are exerted through hyperglycemia or whether it is just an innocent bystander has been increasingly challenged [41–43]. Overt diabetes has been shown to modify the effect on mortality of hyperglycemia [44]. Insulin resistance another feature of diabetes, has been shown to increase the risk of new CVD events [45]. It has been shown that glucose-related risks do exist before levels currently used to define diabetes are reached [46,47]. Intensive glucose lowering has long been known to decrease microvascular complications of diabetes. The ADVANCE study (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) has sprinkled some hope that intensive glucose control may confer some benefit on CVD [2]. In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study increased mortality has been attributed to failing to achieve targets [48]. Traditionally, intensive glucose lowering was not achieved without hypoglycemia [8], weight gain [49], and increased cardiovascular risk (as a side

Table 2 Effects of diabetes and history of cardiovascular disease on mortality from all-cause or cardiovascular disease

|                                | Female          |                                   | Male          |                                   | Total          |                                   |
|--------------------------------|-----------------|-----------------------------------|---------------|-----------------------------------|----------------|-----------------------------------|
|                                | HR (95% CIs) P  | value                            | HR (95% CIs) P | value                            | HR (95% CIs) P | value                            |
| All-cause mortality            |                 |                                   |               |                                   |                |                                   |
| History of cardiovascular disease | 1.47 (0.98-2.20) | 0.061                             | 1.47 (1.03-2.11) | 0.034                             | 1.48 (1.15-1.91) | 0.002                             |
| Diabetes                       | 2.66 (1.83-3.85) | 0.000                             | 1.81 (1.33-2.46) | 0.000                             | 2.06 (1.65-2.57) | 0.000                             |
| Cardiovascular mortality       |                 |                                   |               |                                   |                |                                   |
| History of cardiovascular disease | 1.62 (0.92-2.87) | 0.096                             | 1.70 (1.08-2.68) | 0.022                             | 1.61 (1.13-2.29) | 0.008                             |
| Diabetes                       | 2.76 (1.58-4.80) | 0.000                             | 1.93 (1.28-2.90) | 0.002                             | 2.17 (1.57-3.01) | 0.000                             |

Models were adjusted for age, sex (were not sex-specific), current smoking, systolic blood pressure, using antihypertensive drugs, total and high-density lipoprotein cholesterol.

Table 3 Comparing burden of all-cause mortality due to diabetes with those due to CVD

|                                | Diabetes | History of CVD |
|--------------------------------|----------|----------------|
| Women                          |          |                |
| Prevalence (%)                 | 17.7     | 11.4           |
| HR (95% CIs) P value           | 2.66 (1.83-3.85) | 1.47 (0.98-2.20) |
| Wald $\chi^2$ P value          | 4.65 ($P$ for paired homogeneity test $^2 = 0.031$) |          |
| PAHF (95% CIs)                 | 11.0 (8.4-13.5) | 3.7 (0.0-7.3) |
| RAP (years)                    | 8.6      | 3.1            |
| Men                            |          |                |
| Prevalence (%)                 | 16.3     | 9.3            |
| HR (95% CIs) P value           | 1.81 (1.33-2.46) | 1.47 (1.03-2.11) |
| Wald $\chi^2$ P value          | 1.19 ($P$ for paired homogeneity test $^2 = 0.225$) |          |
| PAHF (95% CIs)                 | 7.9 (5.3-10.5) | 3.0 (0.01-5.7) |
| RAP (years)                    | 7.4      | 4.3            |
| Total                          |          |                |
| Prevalence (%)                 | 17.1     | 10.4           |
| HR (95% CIs) P value           | 2.06 (1.65-2.57) | 1.48 (1.15-1.91) |
| Wald $\chi^2$ P value          | 5.26 ($P$ for paired homogeneity test $^2 = 0.022$) |          |
| PAHF (95% CIs)                 | 9.2 (7.3-11.1) | 3.3 (1.1-5.5) |
| RAP (years)                    | 8.0      | 3.5            |

CVD, cardiovascular disease; HR, hazard ratio; PAHF, population-attributable hazard fraction; RAP, rate advancement period.

1. HRs and their 95% CIs were estimated by implementing the survival proportional hazard (Cox) regression analysis.
2. Wald tests of the linear hypotheses concerning the Cox survival regression models coefficients (paired homogeneity test) were performed to test the null hypotheses that the hazard ratios (effect size) for prevalent diabetes were equal to those for prevalent CVD [32].

$$\text{PAHF} = \frac{p(t)}{P(t)} - \frac{p(0)}{P(0)}$$

where $p(t)$ is the proportion exposed to hypertension at time $t$. We used proportion exposed at baseline. $P = p(0)$.

4. RAP expresses how much sooner a given mortality rate is reached among exposed than among unexposed individuals [30].
effect of glucose lowering agents [2]. It was therefore associated with an increased CVD and all-mortality [4]. Recently, however, there has been an ever-expanding body of evidences on the effectiveness of new approaches to intensify glucose control. New approaches have been shown to reverse diabetes [50], have lower risk of hypoglycemia [51], promote weight loss, and confer decreased CVD risk among diabetic patients. Findings of the current study can, in a population-wide scale, determine the potential borders of the achievement for novel approaches to treat diabetes. Novel therapies can help reduce glucose levels much safer to much lower levels (which would be concomitant reduction in mortality from microvascular complications) meanwhile diabetes-specific modification of atherosclerosis may reduce CVD mortality among diabetic patients. Therefore novel glucose lowering agent may confer a potential for decrease in all-cause mortality. Furthermore, type 2 diabetes has been shown to be prevented or the onset delayed by lifestyle modification, which although involves costs, imposes no harms [52,53].

We are aware that diabetes and CVD are correlated and their effects on outcomes are not mutually exclusive but rather mutually modifiable. Nonetheless, the likelihood ratio test revealed no evidence of significant diabetes × CVD interaction among women. Among men, where interactions were statistically significant, we excluded data on participants with both diabetes and CVD. This subgroup analysis allowed us to directly compare men who had diabetes/without CVD with those who had CVD/without diabetes. We observed that relative importance of the two conditions remained unchanged; our interpretation is, thus, unlikely to have been considerably affected by the effect-modification. Furthermore, allowing for the CVD-modified effects of diabetes simply mean to calculate PAHFs for individuals with diabetes who also had CVD. While it could be theoretically appealing, practically, it is not currently recommended to intensify glucose control among diabetic patients with established macrovascular complications in order to prevent cardiovascular disease [54]. New pharmacologic approaches are on the horizon that offer some hope, though [55].

The clinical implications of the findings reported herein lies in its observable practical consequences. Diabetic patients have residual risk or CVD mortality even after treatment of established CVD risk factors like blood pressure and lipid levels [56]. Approval of glucose-lowering agents may no longer be prudent unless they offer additional beneficial impact on CVD or mortality. Such therapeutic approaches in the light of the current findings will have much potential to improve the population longevity. We await more clinical trials to see if such therapeutic approaches live up to our expectations. The findings of the current study have some public health implications as it allows clinicians more effectively communicate the diabetes-associated risk their patients. For example, a RAP of 8.6 years can be used to explain to a 50-year-old diabetic woman that she has the same risk of death as does a 59-year-old non-diabetic woman.

### Study strengths and limitations

**Strength**

Strength of the present study lies in its prospective nature, the use of a large population-based-cohort of both sexes, accurate and valid data on risk factors at baseline, continuous surveillance of mortality and CVD events based on standard criteria. We used standard methods for measurement of plasma glucose including 2-PCPG.

The fact that we adjusted for established CVD risk

### Table 4 Comparing burden of CVD mortality due to diabetes with those due to CVD

|                         | Diabetes | History of CVD |
|------------------------|----------|----------------|
| **Women**              |          |                |
| Prevalence (%)         | 13.9     | 8.7            |
| HR (95%CI)             | 2.76 (1.58-4.80) | 1.62 (0.92-2.87) |
| Wald χ²                | 1.69 (P for paired homogeneity test = 0.194) |
| PAHF (95%CI)           | 11.5 (7.8-15.0) | 4.9 (3.9-9.4) |
| RAP (years)            | 9.8      | 4.7            |
| **Men**                |          |                |
| Prevalence (%)         | 14.1     | 6.7            |
| HR (95%CI)             | 1.92 (1.28-2.90) | 1.70 (1.08-2.68) |
| Wald χ²                | 0.14 (P for paired homogeneity test = 0.711) |
| PAHF (95%CI)           | 8.0 (4.4-11.5) | 4.3 (1.5-7.1) |
| RAP (years)            | 8.2      | 6.7            |
| **Total**              |          |                |
| Prevalence (%)         | 13.5     | 6.4            |
| HR (95%CI)             | 2.17 (1.57-3.01) | 1.61 (1.13-2.29) |
| Wald χ²                | 1.38 (P for paired homogeneity test = 0.239) |
| PAHF (95%CI)           | 9.4 (6.8-12.0) | 4.5 (1.8-7.0) |
| RAP (years)            | 9.0      | 5.5            |

CVD, cardiovascular disease; HR, hazard ratio; PAHF, population-attributable hazard fraction; RAP, rate advancement period.

1. HRs and their 95% CIs were estimated by implementing the survival proportional hazard (Cox) regression analysis.
2. Wald tests of the linear hypotheses concerning the Cox survival regression models coefficients (paired homogeneity test) were performed to test the null hypotheses that the hazard ratios (effect size) for prevalent diabetes were equal to those for prevalent CVD [32].
3. $PAHF = \frac{\left(1 - e^{-h_{C0}}\right)}{\left(1 - e^{-h_{t}}\right)} - 1$, where $p(t)$ is the proportion exposed to hypertension at time $t$. We used proportion exposed at baseline, $p = p(0)$.
4. RAP expresses how much sooner a given mortality rate is reached among exposed than among unexposed individuals [30].
factors (age, systolic blood pressure, total and HDL cholesterol, cigarette smoking, and use of antihypertensive drugs) makes it unlikely that the strong associations of the all-cause or CVD mortality to diabetes observed here are due to confounding with known risk factors, although in an observational study that possibility can never be definitely excluded. The practical usefulness of RAP in terms of risk communication still waits thorough evaluation. However, its simple calculation and intuitive appeal should make it a worthwhile endeavor [31].

**Limitations**

Some limitations to our study merit mentioning.

1. The number of incident events precluded stratification of analyses by age.
2. Our findings may not apply to individuals of different racial and socioeconomic groups than those in the TLGS population (entirely Persian middle class).
3. We do not have sufficient data to accurately assess the relations of various cause-specific deaths to diabetes. Using aggregate clinical outcome could have potentially attenuated the strength of the associations.
4. Some participants might have developed diabetes or non-fatal CVD during follow up. This misclassification renders our results to regression dilution. Regression dilution, however, biases the estimates towards the null and, thus, is unlikely to have significant affected the results obtained and the interpretations inferred herein.
5. Finally, we only considered glycemic status once intra-individual variability in these measures may have misclassified participants, but this problem would produce an underestimate of the effects of hyperglycemia on outcomes.

**Conclusions**

We have comparatively quantified the public health impact of diabetes and history of previous CVD in terms of all-cause and CVD mortality. We demonstrated that diabetes, which was shown to be keeping pace with previous CVD events in terms of conferring excess risk of incident future CVD events, is currently causing more deaths in the population than do previous CVD events leading to death.

**Competing interests**

The authors declare that they have no competing interests.

**Acknowledgements**

We express our gratitude to the participants of district-13 of Tehran for their enthusiastic support in this study. The statistical helps from Roger B Newson, Mitra Hashemina, and Leila Cheraghi are also highly appreciated.

**Author details**

1. Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences (RIES) Shahid Beheshti University of Medical Science, Tehran, Iran. 2. Endocrine Research Center, Research Institute for Endocrine Sciences (RIES) Shahid Beheshti University of Medical Sciences, Tehran, Iran.

**Authors’ contributions**

MB conceived of and designed the study, carried out the statistical analysis, interpreted the results, and drafted the manuscript. FH, and FA helped critically revised the manuscript. All authors read and approved the final manuscript.

**Financial disclosure**

This study was supported by grant No. 121 from the National Research Council of the Islamic Republic of Iran. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Received**: 12 April 2012   **Accepted**: 15 June 2012

**Published**: 15 June 2012

**References**

1. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulbitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, et al: Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension. New England Journal of Medicine 1999, 340:677–684.
2. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbée D, et al Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572.
3. Edsger TT-F: Disseminating health information in developing countries: the role of the internet. BMJ 2000, 321:797–800.
4. Hemmingens B, Lund SG, Glaud C, Vaag A, Almdal T, Hemmingens C, Wetterslev J: Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011, 343:d6998.
5. Chen G, McAlistier FA, Walker RL, Hemmelgarn BR, Campbell NRC. Cardiovascular Outcomes in Framingham Participants With Diabetes. Hypertension 2011, 57:889–897.
6. Haffner SM, Lehto S, Ronnemaa T, Pyoräli K, Laakso M: Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. New England Journal of Medicine 1998, 339:229–234.
7. Ghosh A, Castle PE: Invited commentary: the importance of prevalence in the effectiveness of a (bio)marker. Am J Epidemiol 2011, 173:1388–1390. discussion 1391.
8. Zounagis S, Patel A, Chalmers I, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, et al. Severe Hypoglycaemia and Risks of Vascular Events and Death. New England Journal of Medicine 2010, 363:1410–1418.
9. Wang WS, Wahiquit ML, Hisu CC, Chang HY, Chang WC, Chen CC. Age-and gender-specific population attributable risks of metabolic disorders on all-cause and cardiovascular mortality in Taiwan. BMC Public Health 2012, 12:111.
10. Harati H, Hadaegh F, Saadat N, Azizi F: Population-based incidence of Type 2 diabetes and its associated risk factors: results from a six-year cohort study in Iran. BMC Public Health 2009, 9:186.
11. Hadaegh F, Bozorgmanesh MR, Ghasemi A, Harati H, Saadat N, Azizi F: High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran Lipid and Glucose Study. BMC Public Health 2008, 8:176.
12. Gomez-Marcos MA, Recio-Rodriguez JL, Patino-Alonso MC, Agudo-Conde C, Gomez-Sanchez L, Rodriguez-Sanchez E, Gomez-Sanchez M, Garcia-Ortiz L:

**Abbreviations**

CHD: Coronary heart disease; CVD: Cardiovascular disease; ECG: Electrocardiography; FPG: Fasting plasma glucose; HDL-C: High-density lipoprotein cholesterol; MI: Myocardial infarction; PAHF: Population-attributable hazard function; PCPG: Post-challenge plasma glucose; RAP: Rate advancement period; TC: Total cholesterol; TLGS: Tehran lipid and glucose study.
Yearly evolution of organ damage markers in diabetes or metabolic syndrome: data from the LOD-DIABETES study. Cardiometabolism 2011; 10:50.

13. Westman M, Etonz D, Danon E: Job insecurity and crossover of burnout in married couples. Journal of Organizational Behavior 2001; 22:467–481.

14. Nash ES: Teenage pregnancy–need a child bear a child. South African Medical Journal 1990; 77:147–151.

15. Trussell J: Teenage pregnancy in the United States, Family Planning Perspectives 1988; 20:262–272.

16. Bozorgmanesh M, Hadaegh F, Sheikholeslami F, Azizi F: Cardiac risk factors and all cause mortality attributable to diabetes: Tehran Lipid and Glucose Study. J Endocrinol Invest 2011; 35:14–20.

17. Saito J, Kubo Y, Yanagisawa K, Iso H, Inoue M, Tsugane S: Diabetes and the risk of coronary heart disease in the general Japanese population: The Japan Public Health Center-based prospective (JPHC) study. Atherosclerosis 2011; 216:187–191.

18. Grau M, Subirana I, Elorza F, Fitó M, Covas MI, Sala J, Masía R, Ramos R, Solanas P, Cordon F: Why should population attributable fractions be periodically recalculated? An example from cardiovascular risk estimation in southern Europe. Preventive medicine 2010; 51:78–84.

19. Kirby D: Emerging answers 2007: Research findings on programs to reduce teen pregnancy and sexually transmitted diseases. National Campaign to Prevent Teen and Unplanned Pregnancy. Retrieved February 2007, 2011-23.

20. Azizi F, Ghanbarian A, Moradian AA, Hadaegh F, Mirravan P, Hedayati M, Mehrabi Y, Zahedi-Ali S: Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II, Trials 2010; 9:10.

21. Bozorgmanesh M, Hadaegh F, Khalili D, Azizi F: Prognostic significance of the Complex "Visceral Adiposity Index" vs. simple anthropometric measures: Tehran Lipid and Glucose Study. Cardiovascular Diabetology 2012; 11:20.

22. Freedman DS, Kahn HS, Mei Z, Grummer-Strawn LM, Dietz WH, Srinivasan SR, Berenson GS: Relation of body mass index and waist-to-height ratio to cardiovascular disease risk factors in children and adolescents: the Bogalusa Heart Study. Am J Clin Nutr 2007; 86:53–40.

23. Hadaegh F, Harati H, Ghanbarian A, Azizi F: Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. Eur J Cardiovasc Prev Rehabil 2006; 13:571–577.

24. Gibbons RJ, Althaus J, Chatterjee K, Dailey J, Deedinga PC, Douglas JS, Ferguson TB Jr, Fihn SD, Freeke TD Jr, Gardin JM, et al: ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina—Annex A: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003, 107:169–198.

25. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, et al: ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction—2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002, 106:1983–1900.

26. Chen YQ, Hu C, Wang Y: Attributable risk function in the proportional hazards model for censored time-event. Biostatistics 2006, 7:515.

27. Samuelson SE, Eide GE: Attributable fractions with survival data. Statistics in Medicine 2008, 27:1447–1461.

28. Silverberg MJ, Smith MW, Chmiel JS, Detels R, Margolick JB, Rinaldo CR, O'Brien SJ, Muzah A: Fraction of Cases of Acquired Immunodeficiency Syndrome Prevented by the Interactions of Identified Restriction Gene Variants. American journal of epidemiology 2004, 159:232–241.

29. Laaksonen MA, Knekt P, Harkkénen T, Virtalä E, Oja H: Estimation of the Population Attributable Fraction for Mortality in a Cohort Study Using a Piecewise Constant Hazards Model. American journal of epidemiology 2010, 171:837–847.

30. Sidiat SH, Buyut VC, Selamat H: Measuring service quality in E-retailing using SERVQUAL model. IJE 2008; 8–7.

31. Liese AD, Hense HW, Brenner H, Lüwell H, Keil U: Assessing the Impact of Classical Risk Factors on Myocardial Infarction by Rate Advancement Periods. American journal of Epidemiology 2000, 152:884–888.

32. Abbate LM, Stevens J, Schwartz TA, Renner JB, Helmick CG, Jordan JM: Anthropometric measures, body composition, body fat distribution, and knee osteoarthritis in women. Obesity (Silver Spring) 2006, 14:1274–1281.

33. Levine B: Peer Reviewed: What Does the Population Attributable Fraction Mean?. Preventing chronic disease 2007, 4:04.

34. Gaegla F, Zenette G, Mazza A, Donadon V, Donada C, Pizzoli A, Tikhonoff N, Palatini P, Pessina AC: Cardiovascular mortality in non-insulin-dependent diabetes mellitus. A controlled study among 683 diabetics and 683 age- and sex-matched normal subjects. European Journal of Epidemiology 2000, 16:677–684.

35. Smith NL, Barzilay J, Kronmal R, Lumley T, Enquobahrie D, Psaty BM: New-Onset Diabetes and Risk of All-Cause and Cardiovascular Mortality. Diabetes Care 2006; 29:2012–2017.

36. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garisdie BK, Wilson PW: Major Risk Factors as Antecedents of Fatal and NonFatal Coronary Heart Disease Events. Jama The Journal of the American Medical Association 2003, 290:891–897.

37. Hoffner SA, Letto S, Ronnemaa T, Pyorala K, Lakka M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.

38. Folsom AR, Szlo M, Stevens J, Liao F, Smith R, Eckfeldt JH: A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 1997, 20:935–942.

39. Paraszcz G: Mortality and survival in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987, 30:123–131.

40. Stengå J, Tuomilehto J, Pekkanen J, Kivini M, Paastra E, Nissinen A, Karvonen M: Diabetes mellitus, impaired glucose tolerance and mortality among elderly men: The Finnish cohorts of the seven country study. Diabetologia 1992, 35:760–765.

41. Buse JB: Should Postprandial Glucose Be Routinely Measured and Treated to a Particular Target?., N Engl J Med 2003, 26:1615–1618.

42. Leosdottir M, Willenheimer R, Persson M, Nilsson PM: The association between glucometabolic disturbances, traditional cardiovascular risk factors and self-rated health by age and gender: A cross-sectional analysis within the Malmö Preventive Project. Cardiovascular Diabetology 2011, 10:118.

43. Nishimura R, Nakaqammt, Tore S, Ohashi Y, Tajima N: Relationship between hemoglobin A1c and cardiovascular disease in mild- to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial. Cardiovascular Diabetology 2011, 10:1–6.

44. Liu Y, Yang Y, Zhu J, Tian H, Liang Y, Li J: Prognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and meta-analysis. Cardiovascular Diabetology 2011, 10:1–9.

45. Verhagen SN, Wassink AM, van der Graaf Y, Corder PM, Vissers FLJ: Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study. Cardiovascular Diabetology 2011, 10:100.

46. Yadegari H, Bozorgmanesh M, Hadaegh F, Azizi F: Non-linear contribution of glucose measures to cardiovascular diseases and mortality: Reclassifying the Framingham's risk categories: A decade follow-up from the Tehran lipid and glucose study. International Journal of Cardiology 2012, 2:--. Epub ahead of print.

47. Srinivas R, Führ M, Kempf M, Martin S, Willenberg HS, Schott M, Dinh W, Scherbaum WA, Lankisch M: A progressive increase in cardiovascular risk assessed by coronary angiography in non-diabetic patients at sub-diabetic glucose levels. Significance 2011, 8:11.

48. Röde MC: Countertrend: Intensive Glucose Control and Mortality in ACCORD—Still Looking for Clues. Diabetes Care 2010, 33:2722.

49. HOOGEWERF RJ: Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD. Cleveland Clinic Journal of Medicine 2008, 75:729–737.

50. Lim E, Hollingsworth K, Aribisala B, Chen M, Mathers J, Taylor R: Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011, 54:2506–2514.
51. Fonseca V, Baron M, Shao Q, Dejager S: Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. *Hormone and metabolic research* 2008, 40:427.

52. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, et al: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001, 344:1343–1350.

53. Harati H, Hadaegh F, Momenan AA, Ghanei L, Bozorgmanesh MR, Ghanbarian A, Mirrman P, Azizi F: Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle eastern community. *Am J Prev Med* 2010, 38:628–636. e621.

54. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, Howard BV, Kirkman MS, Kosiborod M, Reaven P: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. *Circulation* 2009, 119:351–357.

55. Cohen A, Horton ES: Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. *Curr Med Res Opin* 2007, 23:905–917.

56. Nesto RW, Singh PP: Diabetes and residual risk of coronary heart disease. *Nat Clin Pract End Met* 2007, 3:71–71.

doi:10.1186/1475-2840-11-69
Cite this article as: Bozorgmanesh et al.: Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality. *Cardiovascular Diabetology* 2012 11:69.